HRT and Blood Clot Risk: Why the Route of Estrogen Matters

One of the most common concerns I hear about hormone replacement therapy is:

“Does estrogen cause blood clots?”

The answer deserves more explanation than a simple yes or no.

Hormone therapy can affect blood clot risk, but not every type of estrogen therapy carries the same risk, and the way estrogen is delivered matters.

Your age, health history, personal and family history of blood clots, smoking status, weight, medications and other medical conditions matter too.

This is one of the reasons hormone therapy should be individualized rather than treated as one medication with one universal risk profile.

First, What Kind of Blood Clot Are We Talking About?

When we discuss blood clot risk with hormone therapy, we are usually referring to venous thromboembolism, or VTE.

VTE includes:

• Deep vein thrombosis (DVT): a blood clot that usually forms in a deep vein in the leg

• Pulmonary embolism (PE): a clot that travels to the lungs

These can be serious medical conditions.

The important question is not simply whether estrogen has ever been associated with VTE.

It has.

The better question is:

Which estrogen, delivered how, in which patient?

Oral Estrogen and Transdermal Estrogen Are Processed Differently

When estrogen is swallowed as a pill, it travels through the digestive system and then passes through the liver before reaching the general circulation.

This is known as first-pass metabolism.

That liver exposure can affect proteins involved in coagulation and is one reason oral estrogen has been associated with a higher risk of venous blood clots.

Transdermal estrogen is delivered through the skin, such as through a patch, gel or spray.

Because it bypasses first-pass metabolism through the liver, it has a different effect on coagulation pathways.

This distinction is clinically important.

What Does the Research Show?

A large 2019 study published in The BMJ evaluated more than 80,000 women with venous thromboembolism and compared them with nearly 400,000 controls.

The researchers found that oral hormone therapy was associated with an increased risk of VTE compared with no hormone therapy.

The risk also differed depending on the specific estrogen and progestogen formulation used.

In contrast, transdermal preparations were not associated with an increased VTE risk in that study.

That does not mean transdermal estrogen is completely risk-free for every woman.

It means the evidence suggests that route of administration changes the risk profile.

“HRT” Is Not One Medication

This is a point I think gets lost in a lot of conversations about hormone therapy.

When someone says:

“HRT causes blood clots.”

What hormone therapy are we talking about?

Estrogen alone?

Estrogen plus a progestogen?

Oral estrogen?

Transdermal estradiol?

Which dose?

Which progestogen?

How old was the woman when treatment started?

How long had she been menopausal?

What other health risks did she have?

All of those details matter.

Hormone therapy includes different hormones, formulations, doses and delivery methods.

We should not assume they all behave exactly the same way in the body.

The Type of Estrogen Matters Too

The BMJ study also found differences among oral estrogen formulations.

Oral estradiol was associated with a lower VTE risk than oral conjugated equine estrogen in that study, although oral preparations as a group still carried greater risk than transdermal therapy.

The type of progestogen used alongside estrogen may also influence risk.

Again, this is why “HRT” is too broad a term to describe one single risk profile.

Your Personal Risk Factors Matter

The route of estrogen is only part of the decision.

Before prescribing hormone therapy, I also want to understand whether there are other factors that may increase a patient’s baseline risk for blood clots.

These may include:

• A personal history of DVT or pulmonary embolism

• Known clotting disorders

• A strong family history of blood clots

• Smoking

• Obesity

• Increasing age

• Prolonged immobility

• Recent major surgery

• Certain cancers

• Some chronic medical conditions

• Certain medications

A woman without these risk factors may have a very different risk-benefit discussion than someone with several of them.

Individual risk matters more than a blanket statement that hormone therapy is either “safe” or “dangerous.”

Age and Timing Matter Too

Hormone therapy is not evaluated the same way in a healthy woman who begins treatment near the menopause transition as it is in someone beginning systemic therapy decades after menopause.

Age, timing, symptoms and health history all belong in the conversation.

That does not mean every woman should take hormones.

It means hormone therapy should be considered in the context of the individual woman rather than through a one-size-fits-all rule.

What About Vaginal Estrogen?

Low-dose vaginal estrogen is different from systemic estrogen therapy.

Vaginal estrogen used for symptoms such as vaginal dryness, painful intercourse or other genitourinary symptoms generally results in much lower systemic exposure than hormone therapy intended to treat symptoms throughout the body.

It should not automatically be viewed as having the same risk profile as systemic oral estrogen.

This distinction can be especially important for women who need treatment for vaginal and urinary symptoms but are worried about systemic hormone exposure.

What About Estrogen Pellets?

This is where I think it is important to be transparent about the evidence.

We have strong data comparing oral and transdermal estrogen, particularly patches and gels.

There is less high-quality evidence directly comparing every alternative estrogen delivery method, including compounded formulations and implants, with respect to blood clot risk.

That means I would not automatically assume that every therapy that bypasses the stomach has an identical risk profile to a transdermal estradiol patch.

The specific hormone, formulation, dose, delivery method and patient still matter.

That is exactly why treatment decisions should be individualized rather than made from a social-media chart claiming one method is universally “safe” and another is universally “dangerous.”

Does This Mean Oral Estrogen Should Never Be Used?

No.

Medicine rarely works well in absolutes.

Oral estrogen may still be appropriate for some women depending on their health history, preferences, symptoms and overall risk profile.

But if blood clot risk is a concern, the route of estrogen deserves consideration.

That conversation should happen before treatment begins rather than after a prescription has already been chosen.

What About Progesterone?

Women who still have a uterus generally require adequate endometrial protection when systemic estrogen is prescribed.

That often means adding progesterone or a progestogen.

But just as different estrogens are not identical, different progestogens do not necessarily have identical metabolic or clotting effects.

The overall regimen matters.

This is another reason I do not believe hormone therapy should be reduced to:

“Your estrogen is low, so here is estrogen.”

We need to look at the entire treatment plan.

Why I Don’t Like Fear-Based HRT Conversations

Women spent years hearing broad statements such as:

“Hormones cause breast cancer.”

“Estrogen causes heart attacks.”

“HRT causes blood clots.”

Those statements leave out a tremendous amount of context.

At the same time, swinging to the opposite extreme and saying hormone therapy has no risks is not responsible either.

There are risks.

There are benefits.

And both can change based on the person, hormone, formulation, route, dose and timing.

That is the conversation I would rather have.

Hormone Therapy Is a Risk-Benefit Decision

For some women, untreated menopause symptoms significantly affect sleep, quality of life, sexual health and daily functioning.

Estrogen therapy can be highly effective for symptoms such as hot flashes and night sweats.

Hormone therapy can also play an important role in preventing bone loss in appropriately selected women.

Those benefits need to be considered alongside potential risks.

The goal is not to make hormones sound scary.

And the goal is not to sell hormone therapy as risk-free.

The goal is to make a thoughtful decision based on the individual woman.

What Hormone Evaluation Looks Like at AdoreU

Initial Evaluation + Lab Draw

Your first visit begins with a conversation.

We discuss your symptoms, medical history, menstrual history, previous hormone use, medications, personal and family history and what you hope to improve.

We then determine what laboratory testing makes sense for you and draw your initial labs.

Results Review + Treatment Planning

Once your results are available, you return for a comprehensive review.

We go through the laboratory findings together and connect them with your symptoms, health history and goals.

If hormone therapy is appropriate, we discuss the hormones and delivery methods that make sense for you.

Ongoing Monitoring

Starting hormone therapy is not the end of the evaluation.

Symptoms, treatment response, laboratory trends, side effects and changes in your health are monitored over time.

Your plan can change when your needs change.

The Bottom Line

Hormone therapy and blood clot risk cannot be accurately explained with one sentence.

Oral estrogen has been associated with a higher risk of venous blood clots, while transdermal estradiol appears to have a lower VTE risk and was not associated with increased VTE in a large observational study.

But route is only one factor.

Your age, medical history, personal and family history, medications, formulation, dose and other risk factors all matter.

That is why hormone therapy should not start with:

“Which hormone should everyone take?”

It should start with:

“What is appropriate for this person?”

Have Questions About Hormone Therapy?

If you are considering hormone therapy but feel overwhelmed by conflicting information about benefits and risks, a comprehensive evaluation can help you understand your individual options.

AdoreU provides individualized hormone evaluation and hormone optimization for women in O’Fallon, Missouri and throughout St. Charles County.

REQUEST A COMPREHENSIVE ASSESSMENT

References

Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810.